These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 3159226)

  • 1. Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
    Shikano M; Ogawa K; Ito T; Chen LS; Ito Y; Imaizumi M; Uno T; Tsutsumi S; Satake T
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():375-7. PubMed ID: 3159226
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective thromboxane synthetase inhibitor and ischemic heart disease.
    Ito T; Ogawa K; Watanabe J; Chen LS; Shikano M; Imaizumi M; Shibata T; Ito Y; Miyazaki Y; Satake T
    Biomed Biochim Acta; 1984; 43(8-9):S125-32. PubMed ID: 6542777
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise.
    Shikano M; Ito T; Ogawa K; Satake T
    Jpn Heart J; 1987 Sep; 28(5):663-74. PubMed ID: 3323562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans.
    Ito T; Ogawa K; Sakai K; Watanabe J; Satake T; Kayama N; Hiraku S; Naito J
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():245-51. PubMed ID: 6221531
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antithrombotic agents against platelet aggregation].
    Tada M; Kuzuya T; Ohmori M
    Nihon Rinsho; 1983 Dec; 41(12):2781-6. PubMed ID: 6687068
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
    Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical study on effect of thromboxane A2 synthetase inhibitor (OKY-046) to clarify the regulation of cerebral blood flow in cerebral thrombosis.
    Nihei C; Metoki H; Shimanaka Y; Kawahara R; Komatsu O; Oike Y; Kanazawa T; Izawa M; Kaneko H; Hoshi Y
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17B():953-7. PubMed ID: 2960210
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581.
    Casey LC; Fletcher JR; Zmudka MI; Ramwell PW
    J Pharmacol Exp Ther; 1982 Aug; 222(2):441-6. PubMed ID: 6896528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protective effect of a thromboxane synthetase inhibitor, OKY-046, in patients with acute respiratory failure].
    Sakio H; Usui Y; Mita H; Onoda N; Iida M; Okuda C
    Masui; 1984 Sep; 33(9):964-9. PubMed ID: 6542601
    [No Abstract]   [Full Text] [Related]  

  • 10. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
    Aiken JW; Shebuski RJ; Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome.
    Niwa T; Maeda K; Shibata M; Yamada K
    Clin Nephrol; 1988 Nov; 30(5):276-81. PubMed ID: 3214971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
    Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
    Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
    Dale J; Thaulow E; Myhre E; Parry J
    Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboxane synthetase inhibition reduces ventricular irritability after coronary occlusion and reperfusion.
    Austin JC; Berrizbeitia LD; Schoen FJ; Kauffman RP; Hechtman HB; Cohn LH
    Am Heart J; 1988 Mar; 115(3):505-9. PubMed ID: 3344655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats.
    Gomi T; Ikeda T; Ishimitsu T; Uehara Y
    Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serial changes in plasma thromboxane and complement in ARDS--effect of the thromboxane synthetase inhibitor].
    Katoh K; Kani H; Imai T
    Masui; 1985 Jul; 34(7):966-72. PubMed ID: 4057547
    [No Abstract]   [Full Text] [Related]  

  • 17. [The efficacy of prostacyclin (PGI2) and/or OKY-046, a specific thromboxane synthetase inhibitor, in acute myocardial infarction--experimental study].
    Moriuchi M
    Kokyu To Junkan; 1984 Sep; 32(9):955-61. PubMed ID: 6393261
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
    Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046).
    Tomoda H
    Am Heart J; 1986 Oct; 112(4):696-704. PubMed ID: 3532743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.